Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PAC-1 CRISPR/Cas9 KO Plasmid (h): sc-401917
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PAC-1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PAC-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PAC-1 Antibody (4O21): sc-32776
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PAC-1 CRISPR/Cas9 KO Plasmid (h) | sc-401917 | 20 µg | $397.00 |
Overview
Dual specificity phosphatase 2 (DUSP2), also known as PAC-1, is a MAP kinase phosphatase that dephosphorylates activated ERK1/2 and p38, thereby shaping the magnitude and duration of MAPK signaling. In human immune and hematopoietic contexts, DUSP2 contributes to stimulus-dependent control of cytokine-driven transcriptional programs, proliferation, and apoptosis by functioning as a negative feedback regulator of MAPK cascades. Its expression is often inducible in activated lymphocytes and can modulate downstream pathways linked to inflammatory signaling and stress responses. Dysregulated DUSP2 activity or expression has been associated with immune dysfunction and cancer-related signaling phenotypes, making it a useful node for mechanistic studies of MAPK pathway control.
PAC-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DUSP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DUSP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DUSP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PAC-1 protein expression.
This CRISPR knockout system enables efficient generation of DUSP2-deficient cell models for investigation of PAC-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DUSP2 exon(s) critical for PAC-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DUSP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PAC-1 CRISPR/Cas9 KO Plasmid (h) and PAC-1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DUSP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PAC-1 HDR Plasmid (h) and PAC-1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DUSP2 homology arms to support homology-directed repair at defined DUSP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.